Phagenyx

Phagenesis Ltd. is a neurostimulation company focused on restoring swallowing function in patients with neurogenic dysphagia. The company developed Phagenyx®, the pharyngeal electrical stimulation (PES) system designed to promote recovery of safe swallowing by stimulating the pharyngeal neural pathways. Clinical studies and real-world evidence have demonstrated meaningful improvements in swallowing safety, aspiration risk, nasogastric tube removal, and earlier tracheostomy decannulation, particularly in severe and tracheotomized patients.

Phagenesis works closely with researchers and clinical leaders to integrate evidence-based neurostimulation into routine care pathways. With more than 30 scientific publications and growing support from international stroke and dysphagia guidelines, the company is helping shift dysphagia management from compensatory care toward active neurorehabilitation.

By combining clinical evidence, practical bedside workflow integration, and a strong focus on patient recovery, Phagenesis aims to reduce complications such as aspiration pneumonia, accelerate oral feeding, and improve care efficiency across acute and rehabilitation settings.